Ingrezza

Generic name: Valbenazine
Dosage form: capsule (40 mg, 60 mg, 80 mg)
Drug class: VMAT2 inhibitors

Usage of Ingrezza

Ingrezza (valbenazine) is used to treat tardive dyskinesia and chorea associated with Huntington's disease (HD), which are both body movement disorders. Ingrezza works by decreasing the amount of dopamine, in the nerve endings in the brain, which helps control body movements. Ingrezza is from a class of medicines called VMAT2 inhibitors, as it inhibits the vesicular monoamine transporter 2 (VMAT2) in neurons. This medicine controls the symptoms of movement disorders but does not cure the conditions.

Tardive dyskinesia is a nervous system disorder that causes repetitive, uncontrolled muscle movements, usually in the face (chewing, lip smacking, frowning, tongue movement, blinking, or eye movement). Tardive dyskinesia is often caused by long-term treatment with certain psyChiatric medications. Chorea is a movement disorder that results in sudden involuntary movements. It can be caused by Huntington's disease (an inherited disease that causes the progressive breakdown of nerve cells in the brain).

Ingrezza became an FDA-approved medicine on April 11, 2017, for adults with tardive dyskinesia, and on August 18, 2023, and it became approved for the treatment of chorea associated with Huntington's disease. The chorea associated with Huntington's disease approval was based on positive results from the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 that showed an improvement in chorea severity with a statistically significant greater improvement in Total Maximal Chorea (TMC) score when compared to placebo.

Ingrezza side effects

Common Ingrezza side effects

headache, dizziness, drowsiness;

problems with balance or coordination;

dry mouth;

feeling restless;

constipation; or

blurred vision.

Serious Ingrezza side effects

Also see Warnings section below.

Get emergency medical help if you have signs of an allergic reaction to this medicine: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

extreme drowsiness;

fast, slow, or uneven heartbeats;

pounding heartbeats or fluttering in your chest;

shortness of breath; or

a light-headed feeling, like you might pass out; or

Parkinson-like symptoms - tremors, shaking, stiffness, problems with balance or walking.

This is not a complete list of side effects, and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Ingrezza

You should not use this medicine if you are allergic to valbenazine or any ingredients contained in this medicine, click here for a full list of ingredients

To make sure this medicine is safe for you, tell your doctor if you have ever had:

heart disease;

long QT syndrome or other heart rhythm disorder;

congestive heart failure;

a heart attack;

liver disease; or

kidney disease.

Pregnancy

Ingrezza may cause fetal harm. Tell your doctor if you are pregnant, become pregnant, or plan to become pregnant.

Breastfeeding

Do not breastfeed while using this medicine and for at least 5 days after your last dose.

Relate drugs

How to use Ingrezza

Usual Adult Dose for Tardive Dyskinesia:

Initial Dose: 40 mg orally once a day

Maintenance Dose: Increase to 80 mg orally once a day after one week at the initial dose; however, a continuation of the initial dose may be considered for some patients.

Usual Adult Dose for Chorea associated with Huntington’s disease:

Initial dose: 40 mg once daily.

Maintenance Dose: Increase the dose in 20 mg increments every two weeks to the recommended dosage of 80 mg once daily.

Comments:

Administer with or without food.

The recommended dosage for patients with moderate or severe hepatic impairment is 40 mg once daily.

The recommended dosage for known CYP2D6 poor metabolizers is 40 mg once daily.

Ingrezza capsules are available as 40 mg, 60 mg, and 80 mg.

Warnings

This mediicne can cause:

Depression and suicidal ideation and behavior are observed in patients with Huntington’s disease.

Hypersensitivity, including angioedema, may occur. Treatment should be discontinued if this occurs.

Somnolence and sedation may impair the patient’s ability to drive or operate hazardous machinery.

QT Prolongation: There may be an increase in QT interval. Usage should be avoided in patients with congenital long QT syndrome or arrhythmias associated with prolonged QT interval.

Neuroleptic Malignant Syndrome (NMS) may occur. Treatment should be discontinued if this syndrome is observed.

Parkinsonism: Some patients have reported Parkinson-like symptoms, including severe cases, during the postmarketing period. The dose of this medicine should be reduced or discontinued if clinically significant Parkinson-like signs or symptoms develop.

What other drugs will affect Ingrezza

Other drugs may interact with this medicine, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

It is important to tell your doctor if you take any of these medicines.

Monoamine oxidase inhibitors (MAOIs).

Strong CYP3A4 inducers

Strong CYP3A4 inhibitors

Strong CYP2D6 inhibitors

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.